Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

Michele Merli, Andrea Ferrario, Margherita Maffioli, Luca Arcaini, Francesco Passamonti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: The advent of the anti-CD20 mAb rituximab has opened a new era in the treatment of non-Hodgkin's lymphomas (NHL), markedly altering standard treatment strategies. Moreover, the proof-of-concept that targeting a specific lymphocyte surface antigen may induce a highly effective and safe targeted killing of malignant cells has opened the door to the development of a plethora of novel mAbs directed towards different B- and T-cell-specific antigens.Areas covered: This review discusses the recent available clinical data about new-generation anti-CD20 mAbs characterized by increased antibody- (obinutuzumab) or complement-dependent cyotoxicity (ofatumumab) as well as novel investigational agents targeting other lymphocyte antigens (e.g., CD19, CD22, CD30, CD40, CD52, CCR4), which are currently under investigation for B- and T-cell NHL treatment. In addition, antibody-drug conjugates (inotuzumab ozogamicin, brentuximab vedotin, polatuzumab vedotin), bispecific T-cell engagers (blinatumomab) and a new class of antibodies targeting cytotoxic T-lymphocyte-associated antigen 4, programmed death 1 or programmed death ligand 1 (immune checkpoint inhibitors) are specifically considered.Expert opinion: Among the novel mAbs challenging rituximab, obinutuzumab seems to be in the most advanced phase, with the results of randomized trials awaited shortly. Brentuximab vedotin is increasing its role in T-cell NHL. Furthermore, immune checkpoint inhibitors have the potential to acquire a great relevance in NHL therapy.

Original languageEnglish
Pages (from-to)897-912
Number of pages16
JournalExpert Opinion on Investigational Drugs
Volume24
Issue number7
DOIs
Publication statusPublished - Jul 1 2015

Fingerprint

Investigational Therapies
Non-Hodgkin's Lymphoma
Lymphocytes
Antigens
T-Cell Lymphoma
CD19 Antigens
CTLA-4 Antigen
T-Lymphocytes
Antibodies
Immunoglobulin Isotypes
Expert Testimony
Therapeutics
Surface Antigens
Ligands
Pharmaceutical Preparations
obinutuzumab
Rituximab
cAC10-vcMMAE

Keywords

  • Antibody-drug conjugates
  • Bispecific T-cell engagers
  • CD20
  • CD30
  • CTLA-4
  • Immune checkpoint inhibitors
  • MAb
  • Non-Hodgkin's lymphoma
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. / Merli, Michele; Ferrario, Andrea; Maffioli, Margherita; Arcaini, Luca; Passamonti, Francesco.

In: Expert Opinion on Investigational Drugs, Vol. 24, No. 7, 01.07.2015, p. 897-912.

Research output: Contribution to journalArticle

Merli, Michele ; Ferrario, Andrea ; Maffioli, Margherita ; Arcaini, Luca ; Passamonti, Francesco. / Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma. In: Expert Opinion on Investigational Drugs. 2015 ; Vol. 24, No. 7. pp. 897-912.
@article{24c3773d391d4919b8999d40ea955f8c,
title = "Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma",
abstract = "Introduction: The advent of the anti-CD20 mAb rituximab has opened a new era in the treatment of non-Hodgkin's lymphomas (NHL), markedly altering standard treatment strategies. Moreover, the proof-of-concept that targeting a specific lymphocyte surface antigen may induce a highly effective and safe targeted killing of malignant cells has opened the door to the development of a plethora of novel mAbs directed towards different B- and T-cell-specific antigens.Areas covered: This review discusses the recent available clinical data about new-generation anti-CD20 mAbs characterized by increased antibody- (obinutuzumab) or complement-dependent cyotoxicity (ofatumumab) as well as novel investigational agents targeting other lymphocyte antigens (e.g., CD19, CD22, CD30, CD40, CD52, CCR4), which are currently under investigation for B- and T-cell NHL treatment. In addition, antibody-drug conjugates (inotuzumab ozogamicin, brentuximab vedotin, polatuzumab vedotin), bispecific T-cell engagers (blinatumomab) and a new class of antibodies targeting cytotoxic T-lymphocyte-associated antigen 4, programmed death 1 or programmed death ligand 1 (immune checkpoint inhibitors) are specifically considered.Expert opinion: Among the novel mAbs challenging rituximab, obinutuzumab seems to be in the most advanced phase, with the results of randomized trials awaited shortly. Brentuximab vedotin is increasing its role in T-cell NHL. Furthermore, immune checkpoint inhibitors have the potential to acquire a great relevance in NHL therapy.",
keywords = "Antibody-drug conjugates, Bispecific T-cell engagers, CD20, CD30, CTLA-4, Immune checkpoint inhibitors, MAb, Non-Hodgkin's lymphoma, PD-1, PD-L1",
author = "Michele Merli and Andrea Ferrario and Margherita Maffioli and Luca Arcaini and Francesco Passamonti",
year = "2015",
month = "7",
day = "1",
doi = "10.1517/13543784.2015.1038342",
language = "English",
volume = "24",
pages = "897--912",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

AU - Merli, Michele

AU - Ferrario, Andrea

AU - Maffioli, Margherita

AU - Arcaini, Luca

AU - Passamonti, Francesco

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Introduction: The advent of the anti-CD20 mAb rituximab has opened a new era in the treatment of non-Hodgkin's lymphomas (NHL), markedly altering standard treatment strategies. Moreover, the proof-of-concept that targeting a specific lymphocyte surface antigen may induce a highly effective and safe targeted killing of malignant cells has opened the door to the development of a plethora of novel mAbs directed towards different B- and T-cell-specific antigens.Areas covered: This review discusses the recent available clinical data about new-generation anti-CD20 mAbs characterized by increased antibody- (obinutuzumab) or complement-dependent cyotoxicity (ofatumumab) as well as novel investigational agents targeting other lymphocyte antigens (e.g., CD19, CD22, CD30, CD40, CD52, CCR4), which are currently under investigation for B- and T-cell NHL treatment. In addition, antibody-drug conjugates (inotuzumab ozogamicin, brentuximab vedotin, polatuzumab vedotin), bispecific T-cell engagers (blinatumomab) and a new class of antibodies targeting cytotoxic T-lymphocyte-associated antigen 4, programmed death 1 or programmed death ligand 1 (immune checkpoint inhibitors) are specifically considered.Expert opinion: Among the novel mAbs challenging rituximab, obinutuzumab seems to be in the most advanced phase, with the results of randomized trials awaited shortly. Brentuximab vedotin is increasing its role in T-cell NHL. Furthermore, immune checkpoint inhibitors have the potential to acquire a great relevance in NHL therapy.

AB - Introduction: The advent of the anti-CD20 mAb rituximab has opened a new era in the treatment of non-Hodgkin's lymphomas (NHL), markedly altering standard treatment strategies. Moreover, the proof-of-concept that targeting a specific lymphocyte surface antigen may induce a highly effective and safe targeted killing of malignant cells has opened the door to the development of a plethora of novel mAbs directed towards different B- and T-cell-specific antigens.Areas covered: This review discusses the recent available clinical data about new-generation anti-CD20 mAbs characterized by increased antibody- (obinutuzumab) or complement-dependent cyotoxicity (ofatumumab) as well as novel investigational agents targeting other lymphocyte antigens (e.g., CD19, CD22, CD30, CD40, CD52, CCR4), which are currently under investigation for B- and T-cell NHL treatment. In addition, antibody-drug conjugates (inotuzumab ozogamicin, brentuximab vedotin, polatuzumab vedotin), bispecific T-cell engagers (blinatumomab) and a new class of antibodies targeting cytotoxic T-lymphocyte-associated antigen 4, programmed death 1 or programmed death ligand 1 (immune checkpoint inhibitors) are specifically considered.Expert opinion: Among the novel mAbs challenging rituximab, obinutuzumab seems to be in the most advanced phase, with the results of randomized trials awaited shortly. Brentuximab vedotin is increasing its role in T-cell NHL. Furthermore, immune checkpoint inhibitors have the potential to acquire a great relevance in NHL therapy.

KW - Antibody-drug conjugates

KW - Bispecific T-cell engagers

KW - CD20

KW - CD30

KW - CTLA-4

KW - Immune checkpoint inhibitors

KW - MAb

KW - Non-Hodgkin's lymphoma

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=84934909085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934909085&partnerID=8YFLogxK

U2 - 10.1517/13543784.2015.1038342

DO - 10.1517/13543784.2015.1038342

M3 - Article

C2 - 25900401

AN - SCOPUS:84934909085

VL - 24

SP - 897

EP - 912

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 7

ER -